title: [Reactivity and communication of Health Authorities toward health professionals: a public health priority].
abstract: OBJECTIVE
  evaluate the impact of Health Authorities' communication on medical practices through 2 examples: celecoxib, taking into account the recent countra indication related to cardio vascular risks; pergolide, taking into account the risk of cardiac valvulopathy.
  
  
  METHODS
  Use of the Pays de Loire Health Insurance Administration data base to monitor the number of cardio vascular patients at risk who receive celecoxib, and cardiac surveillance of pergolide exposed patients.
  
  
  RESULTS
  Communication from Health Authorities resulted in a major decrease (71.9%) of the number of risking patients who take celecoxib, and a significant 14% decrease of pergolide treated patients needing cardiac monitoring
  
  
  CONCLUSIONS
  Unlike the information related to pergolide, the information related to celecoxib was fully taken into account. The difference seems to come from the fact that one was widely relayed by medias, not the other.
authors.affiliation: Service de Pharmacologie Clinique, CHU de Nantes, Institut de Biologie, Nantes, France. caroline.vigneau@chu-nantes.fr
authors.forename: Caroline
authors.initials: C
authors.lastname: Victorri-Vigneau
authors.forename: Marie
authors.initials: M
authors.lastname: Marais
authors.forename: Gwenaëlle
authors.initials: G
authors.lastname: Veyrac
authors.forename: Anicet
authors.initials: A
authors.lastname: Chaslerie
authors.forename: Jacques
authors.initials: J
authors.lastname: Pivette
authors.forename: Pascale
authors.initials: P
authors.lastname: Jolliet
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D005602:France; D006801:Humans; D033183:Interdisciplinary Communication; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use; D011634:Public Health / Q000706:statistics & numerical data*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D010479:Pergolide; D000068579:Celecoxib